Finding. Before a monocyte enters a calcified aortic valve, the valve's own jet has already rewritten it. Lai, Peter, Baratchi and colleagues push monocytes through an engineered stenosis at pathological shear and watch the proteome and phosphoproteome move toward metabolism, cytoskeleton, and inflammation. Protein kinase C activity rises. AKT is suppressed. Actin polymerizes. Calcium signaling increases. Mitochondrial membrane potential goes up. Put those pre-sheared cells into a glycosaminoglycan-rich matrix that mimics stenotic valve tissue and they become a mixed CD80/CD163 macrophage that takes up less oxidized LDL and makes fewer foam cells. A myeloid Piezo1 knockout says the ion channel is the sensor that links shear to PKC, to mitochondria, and to that lasting phenotype.
Why this paper matters
Calcific aortic valve disease has no drug. The usual immune story starts after recruitment. This preprint starts in the bloodstream, where the narrowing itself is a mitochondrial and kinase classroom. Piezo1 is a named handle. Mitochondrial membrane potential is on the mechanical path, not a decorative stress stain.
They also built TAVI into the logic: if restoring physiological flow in patients reverses the shear phenotype, the monocyte state is haemodynamic, not a fixed myeloid disease. The abstract introduces that clinical arm more clearly than it reports its result, so do not invent a TAVI-cures-monocytes headline from this brief.
What they actually measured
Engineered shear, deep phospho-proteomics, kinase inference (PKC up, AKT down), live-cell actin/calcium/membrane-potential/PKC, a valve-like matrix differentiation assay, and myeloid Piezo1 genetics. Foam-cell and CD80/CD163 readouts sit on the matrix side.
How to read the score
Around 80. Mechanistic Piezo1-PKC-mitochondria chain in a disease with no medical therapy. Confidence is medium for the human TAVI claim and for what high membrane potential actually means.
Caveats
Membrane potential is not a respiratory phenotype. Mixed macrophage markers are not a clinical benefit. TAVI reversal needs the patient data, not the experimental rationale.
What to do with it
If you model myeloid mitochondria in aortic stenosis, add a shear pre-treatment and a Piezo1 arm. Pull the PKC/AKT polarity. Do not start a Piezo1 inhibitor trial from this brief.